Medtronic OCI Attributable to Noncontrolling Interest increased by 133.3% to $7.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $7.00M to $7.00M.
Fluctuations reflect the impact of external market factors on the equity stakes held by minority partners.
This metric captures the share of other comprehensive income or loss that is allocated to noncontrolling interest holder...
Common in companies with complex joint venture structures or partially owned international operations.
c_other_comprehensive_income_loss_noncontrolling_interest| Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | Q2 '26 | Q3 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.00M | $5.00M | $4.00M | $0.00 | $6.00M | $11.00M | $6.00M | $0.00 | $17.00M | $6.00M | $9.00M | $7.00M | $8.00M | $3.00M | $7.00M |
| QoQ Change | — | +25.0% | -20.0% | -100.0% | — | +83.3% | -45.5% | -100.0% | — | -64.7% | +50.0% | -22.2% | +14.3% | -62.5% | +133.3% |
| YoY Change | — | — | — | -100.0% | +20.0% | +175.0% | — | -100.0% | +54.5% | +0.0% | — | -58.8% | +33.3% | -66.7% | +0.0% |